Used in the treatment of acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as those involving the FLT3 gene. It functions as a targeted protein degrader, specifically designed to selectively degrade the transcription factor GSPT1, which plays a key role in protein synthesis and cell proliferation. By inducing degradation of GSPT1, the compound triggers cancer cell death while sparing normal cells to a greater extent than traditional chemotherapies. Currently investigated in clinical trials for its efficacy and safety profile, it represents a promising approach in precision oncology.